Lipoprotein-associated paf (LA-paf) was found in washed human platelets and monocyte/macrophage-like U937 cells.
Beyond cholesterol, inflammatory ether phospholipids such as platelet-activating factor (paf) may play a role in atherogenesis. (1) We detected a paf-like compound ('LA-paf') associated with human serum lipoproteins, mainly in LDL but not with the lipoprotein-poor fraction. (2) LA-paf was also found in washed human platelets, from where it was partially released during platelet aggregation in response to paf (50 nM) or thrombin (1 U). In addition, resident monocyte/macrophage-like U937 cells carried huge amounts of LA-paf (41 ng per 10(7) cells) and metabolized added [3H]paf to a labelled compound co-eluting with the retention time of LA-paf in standard HPLC. (3) Functionally, LA-paf had a comparable potency to synthetic paf, because LA-paf aggregated washed aspirin-treated platelets in a concentration-dependent manner. The specific paf receptor antagonist WEB2086 inhibited the platelet aggregation induced by three distinct LA-paf preparations as compared with synthetic paf with similar inhibitory concentrations (IC50: 35.6 +/- 12.8, 24.0 +/- 4.0, 38.0 +/- 15.8 nM for LA-paf, and 43.6 +/- 6.5 nM for synthetic paf), indicating that LA-paf interacted with paf receptors. (4) However, LA-paf had a distinct retention time using high-pressure liquid chromatography (HPLC) as compared with synthetic paf. LA-paf eluted at 9-15 min and synthetic paf at 21-24 min. In addition, total and non-specific [3H]paf binding to intact washed human platelets was affected differently by the two unlabelled agonists: while LA-paf increased total and non-specific (but not specific) binding in a significant manner (P < 0.002 and P < 0.007) as LDL did (P < 0.006 and P < 0.03), synthetic paf decreased total binding (P < 0.03). Similarly, low-density lipoproteins (LDL) increased significantly the total [3H]paf binding. In contrast, paf did not affect specific [125I]LDL binding to human fibroblasts. Our results show the presence of LA-paf in lipoproteins, washed human platelets and monocyte/macrophage-like cells. As LDL and LA-paf purified from the same LDL particles increased significantly the total [3H]paf binding to intact human platelets, it might modulate platelet adherence to vascular endothelial cells.
Korth
R
R
Forschung in der Allgemeinmedizin FIDA bei dem INSERM U200, München, Germany.
Zimmermann
K
K
Richter
W O
WO
D000818:Animals; D001792:Blood Platelets / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D002784:Cholesterol / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007457:Iodine Radioisotopes; D008077:Lipoproteins, LDL / Q000097:blood* / Q000378:metabolism / Q000494:pharmacology*; D008264:Macrophages / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D009000:Monocytes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000378:metabolism* / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors; D011817:Rabbits; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014316:Tritium
D007457:Iodine Radioisotopes; D008077:Lipoproteins, LDL; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D014316:Tritium; D002784:Cholesterol